Doxorubicin nephrotoxicity in cats (Felis catus) with malignant mammary neoplasms

ABSTRACT The aim of the study was to investigate nephrotoxicity doxorubicin in cats with malignant neoplasms mammary gland. All selected did not present comorbidities such as nephropathies and/or cardiomyopathies, confirmed by physical and laboratory tests, underwent radical mastectomy associated regional lymph node excision were treated a protocol based on doxorubicin. Renal markers urea, creatinine, symmetrical dimethylarginine evaluated during all treatment, two months after end. Abdominal ultrasound, urinalysis biochemical analysis protein, urinary creatinine GGT performed beginning end evaluate possible renal alterations. Six alterations any exams study. Two presented azotemia this study, one them stopped treatment early, because intense azotemia. Clinical imaging monitoring patients throughout is essential, including measurement analytes that detect kidney changes early. Thus, it emphasized safe drug for use non-nephropathic cats.